The FDA is to give AstraZeneca’s cancer drug acalabrutinib a fast review in a rare blood cancer, as the company hopes to shake off disappointing results from a crucial lung cancer trial last week.

This finding is most noticeable in those taking a BTKi drug such as ibrutinib or acalabrutinib. Previous evidence from observational studies suggested that pausing the BTKi drug around the time of ...